Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Enters Into $10B Loan Agreements

NEW YORK – Danaher said in a regulatory filing on Thursday it has replaced its current credit facility with an amended $5 billion revolving credit facility agreement.

The Washington, DC-based company also announced it has entered into a new $5 billion revolving credit facility. 

The amended credit facility, disclosed in a document filed with the US Securities and Exchange Commission, replaces the company’s previous $4 billion unsecured revolving credit facility. 

The amended loan expires on Aug. 27, 2024, but could be extended another year at Danaher’s request. 

In addition, the company can request up to five increases of $2.5 billion total.

The firm also announced a new $5 billion revolving credit facility, which expires Aug. 25, 2020. Danaher can choose to pay a .75 percent fee and convert the outstanding loan to a term loan payable a year later.

Bank of America was the administrative agent for both loans.

Danaher said it intends to use the loans to add liquidity support for its expanded US and European commercial paper programs and for general corporate purposes. Proceeds from the commercial paper notes will be used for Danaher’s planned $21.4 billion acquisition of GE Life Sciences’ Biopharma business.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.